Advertisement

BioNanoScience

, Volume 8, Issue 3, pp 916–923 | Cite as

Influence of Standardized Extract Ginkgo biloba EGb761® Towards Quality of Life Indicators in Patients with Diabetes Mellitus Type 2

  • Radiy EsinEmail author
  • Oleg Esin
  • Ilshat Khayrullin
Article
  • 54 Downloads

Abstract

Cognitive impairment in patients with type 2 diabetes mellitus (DM-2) currently attracts a lot of attention due to their impact on quality of life and the effectiveness of treatment. The aim of research is to find the most effective medication which influences the cognitive functions positively. The research included 120 patients with average age of 61.22 ± 8.6 and average DM-2 duration of 10.84 ± 8.2 years. Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA test), Trail Making Test (TMT), Parts A and B, Hospital Anxiety and Depression Scale (HADS), and The Short Form-36 (SF-36) were used. It was revealed that patients with DM type 2 had cognitive dysfunction generally presented by mild cognitive impairment. Patients with DM-2 have an early manifestation of cognitive impairment. After the initial estimation of indicators, all the patients were taking standardized extract Ginkgo biloba (EGb 761®) in the dose 240 mg a day for 6 months. Estimation of all the indicators after 3 and 6 months of treatment showed significant cognitive improvement. By matching the available experimental and clinical data, we can conclude that in the setting of DM-2 EGb 761®, by producing a positive effect towards various factors which results from insulin resistance of the brain, improves functions of the brain, which manifests in improvement of main QoL indicators in DM-2.

Keywords

Diabetes mellitus type 2 Cognitive decline EGb 761 Quality of life Neurocognitive tests 

Notes

Funding Information

The reported study was supported by the program of competitive growth of Kazan Federal University.

References

  1. 1.
    Global report on diabetes. [Internet]. Apps.who.int. 2018 [cited 27 March 2018]. Available from: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf.
  2. 2.
    Quality of Life Assessment: an annotated bibliography [Internet]. Apps.who.int. 1994 [cited 27 March 2018]. Available from: http://apps.who.int/iris/bitstream/10665/61629/1/WHO_MNH_PSF_94.1.pdf.
  3. 3.
    Bosic-Zivanovic, D., Medic-Stojanoska, M., & Kovacev-Zavisic, B. (2012). The quality of life in patients with diabetes mellitus type 2. Vojnosanitetski Pregled, 69(10), 858–863.CrossRefGoogle Scholar
  4. 4.
    Esin, R., Khairullin, I., Esin, O., & Abakumova, A. (2016). Quality of life in patients with type 2 diabetes mellitus. BioNanoScience, 6(4), 502–507.CrossRefGoogle Scholar
  5. 5.
    Folstein, M., Folstein, S., & McHugh, P. (1975). Mini-mental state. Journal of Psychiatric Research, 12(3), 189–198.CrossRefGoogle Scholar
  6. 6.
    MoCA Montreal—cognitive assessment [Internet]. MoCA Montreal—cognitive assessment. [cited 27 March 2018]. Available from: http://www.mocatest.org/wp-content/uploads/2015/tests-instructions/MoCA-Test-Russian_2010.pdf.
  7. 7.
    Atkinson, T., & Ryan, J. (2007). The use of variants of the trail making test in serial assessment. Journal of Psychoeducational Assessment, 26(1), 42–53.CrossRefGoogle Scholar
  8. 8.
    Zigmond, A., & Snaith, R. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.CrossRefGoogle Scholar
  9. 9.
    Ware, J., Snow, K., Kosinski, M., & Gandek, B. (1997). SF-36 health survey. Boston: The Health Institute, New England Medical Center.Google Scholar
  10. 10.
    Lim, S., Yoon, J., Kang, S., Choi, S., Cho, B., Kim, M., et al. (2011). EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. PLoS One, 6(6), e20301.CrossRefGoogle Scholar
  11. 11.
    Silva, G. (2011). Neuroprotective action of Ginkgo biloba on the enteric nervous system of diabetic rats. World Journal of Gastroenterology, 17(7), 898.CrossRefGoogle Scholar
  12. 12.
    Saini, A., Taliyan, R., & Sharma, P. (2014). Protective effect and mechanism of Ginkgo biloba extract-EGb 761 on STZ-induced diabetic cardiomyopathy in rats. Pharmacognosy Magazine, 10(38), 172.CrossRefGoogle Scholar
  13. 13.
    Welt, K., Weiss, J., Martin, R., Hermsdorf, T., Drews, S., & Fitzl, G. (2007). Ginkgo biloba extract protects rat kidney from diabetic and hypoxic damage. Phytomedicine, 14(2–3), 196–203.CrossRefGoogle Scholar
  14. 14.
    Wei, Z., Wei, Z., ShanShan, X., & QiChong, X. (2013). GW24-e2480 Ginkgo biloba attenuates oxidative DNA damage of human umbilical vein endothelial cells induced by intermittent high glucose. Heart, 99(Suppl 3), A95.2–A9A96.CrossRefGoogle Scholar
  15. 15.
    Liu, X., Hao, W., Qin, Y., Decker, Y., Wang, X., Burkart, M., et al. (2015). Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer’s disease. Brain, Behavior, and Immunity, 46, 121–131.CrossRefGoogle Scholar
  16. 16.
    Xie, H., Wang, J., Yau, L., Liu, Y., Liu, L., Han, Q., et al. (2014). Catechins and procyanidins of Ginkgo biloba show potent activities towards the inhibition of β-amyloid peptide aggregation and destabilization of preformed fibrils. Molecules, 19(4), 5119–5134.CrossRefGoogle Scholar
  17. 17.
    Talbot, K., Wang, H., Kazi, H., Han, L., Bakshi, K., Stucky, A., et al. (2012). Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. Journal of Clinical Investigation, 122(4), 1316–1338.CrossRefGoogle Scholar
  18. 18.
    Blazquez, E., Velazquez, E., Hurtado-Carneiro, V., Ruiz-Albusac, J. (2014). Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and Alzheimer’s disease. Frontiers in Endocrinology, 5.Google Scholar
  19. 19.
    Derakhshan, F., & Toth, C. (2013). Insulin and the brain. Current Diabetes Reviews, 9(2), 102–116.Google Scholar
  20. 20.
    Cong, W., Tao, R., Tian, J., Zhao, J., Liu, Q., & Ye, F. (2011). EGb761, an extract of Ginkgo biloba leaves, reduces insulin resistance in a high-fat-fed mouse model. Acta Pharmaceutica Sinica B, 1(1), 14–20.CrossRefGoogle Scholar
  21. 21.
    EGb 761 prevented palmitate-induced insulin resistance in L6 myotubes via the inhibition of stress kinases, NF-[kappa]B, and PK [theta] | American Diabetes Association [Internet]. Professional.diabetes.org. 2007 [cited 30 March 2018]. Available from: https://professional.diabetes.org/abstract/egb-761-prevented-palmitate-induced-insulin-resistance-l6-myotubes-inhibition-stress.
  22. 22.
    Kudolo, G., Wang, W., Javors, M., & Blodgett, J. (2006). The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects—a double blind placebo-controlled, crossover study. Clinical Nutrition, 25(4), 606–616.CrossRefGoogle Scholar
  23. 23.
    Zhang, Y., Zhao, Y., Pan, F., & Zhang, P. (2016). EGb761 attenuates depressive-like behaviours induced by long-term light deprivation in C57BL/6J mice through inhibition of NF-κB-IL-6 signalling pathway. Central European Journal of Immunology, 4, 350–357.CrossRefGoogle Scholar
  24. 24.
    Rojas, P., Serrano-García, N., Medina-Campos, O., Pedraza-Chaverri, J., Ögren, S., & Rojas, C. (2011). Antidepressant-like effect of a Ginkgo biloba extract (EGb761) in the mouse forced swimming test: role of oxidative stress. Neurochemistry International, 59(5), 628–636.CrossRefGoogle Scholar
  25. 25.
    Yeh, K., Wu, C., Tai, M., & Tsai, Y. (2011). Ginkgo biloba extract enhances noncontact erection in rats: the role of dopamine in the paraventricular nucleus and the mesolimbic system. Neuroscience, 189, 199–206.CrossRefGoogle Scholar
  26. 26.
    Kehr, J., Yoshitake, S., Ijiri, S., Koch, E., Nöldner, M., & Yoshitake, T. (2012). Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®. International Psychogeriatrics, 24(S1), S25–S34.CrossRefGoogle Scholar
  27. 27.
    Preuss, U., Bachinskaya, N., Kaschel, R., Wong, J., Hoerr, R., & Gavrilova, S. (2013). 1689—Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized placebo-controlled trial. European Psychiatry, 28, 1.CrossRefGoogle Scholar
  28. 28.
    Gavrilova, S., Preuss, U., Wong, J., Hoerr, R., Kaschel, R., & Bachinskaya, N. (2014). Efficacy and safety of Ginkgo biloba extract EGb 761®in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. International Journal of Geriatric Psychiatry, 29(10), 1087–1095.CrossRefGoogle Scholar
  29. 29.
    Hoerr, R., Nacu, A. (2016). Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761® treatment: Additional results from a 24-week randomized, placebo-controlled trial. Open Access Journal of Clinical Trials, 1.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Laboratory of Clinical LinguisticsKazan Federal UniversityKazanRussia
  2. 2.Department of Neurology and Manual TherapyKazan State Medical AcademyKazanRussia
  3. 3.Department of Fundamental Basis of Clinical MedicineKazan Federal UniversityKazanRussia
  4. 4.Department of Russian Language and Applied LinguisticsKazan Federal UniversityKazanRussia

Personalised recommendations